Compare Ascendis Pharma A/S (ASND) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Procter & Gamble Co — how do they compare? Ascendis Pharma A/S trades at $263.68 (market cap $17.74B), while Procter & Gamble Co trades at $147.47 (market cap $342.40B). The key difference: Procter & Gamble Co is far larger — about 19.3× Ascendis Pharma A/S's market cap, and Procter & Gamble Co pays a 2.9% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PG | |
|---|---|---|
Market Cap | $17.74B | $342.40B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $167.18 |
52-Week Low | $163.32 | $138.10 |
Enterprise Value | $18.11B | $367.88B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Procter & Gamble (PG) trades at $147.36, up 0.22% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 19.16% net margin. The stock shows stable revenue growth, with 2025 revenue at $84.28B, and benefits from a recent dividend payment of $1.09 per share. Analyst consensus is bullish with a $159.75 price target, though technical indicators highlight resistance near $148.
PG offers a defensive investment with reliable dividends and solid cash flow, but faces risks from premium valuation and modest growth. Near-term upside depends on Q2 2026 earnings meeting expectations, while macroeconomic pressures could limit gains. Institutional sentiment remains positive, supporting a hold or buy stance for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
